Published in Cancer Res on November 01, 1999
Targeting neovascular pericytes in neurofibromatosis type 1. Angiogenesis (2005) 1.04
Antiangiogenic properties of substituted (Z)-(±)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives. Bioorg Med Chem Lett (2010) 0.89
The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. PLoS One (2010) 0.88
Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models. Genet Vaccines Ther (2009) 0.82
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (1997) 4.70
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res (1999) 4.23
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature (1996) 3.40
Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A (1972) 3.24
Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem (1995) 3.13
Appearance of T-cell markers in bone marrow rosette-forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci U S A (1971) 3.13
Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia (2005) 3.10
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res (2000) 2.39
Roles for Fgf signaling during zebrafish fin regeneration. Dev Biol (2000) 2.36
Divergent orientation of transcription from the biotin locus of Escherichia coli. J Mol Biol (1971) 2.18
Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg (1998) 2.17
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. Proc Natl Acad Sci U S A (1987) 1.98
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J (2001) 1.86
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res (2001) 1.80
Controls and polarity of transcription during bacteriophage T4 development. J Mol Biol (1971) 1.77
Fractionation of the complementary strands of coliphage T4 DNA based on the asymmetric distribution of the poly U and poly U,G binding sites. Virology (1968) 1.75
Ontogenesis of cell-mediated immunity in murine thymocytes and spleen cells and its acceleration by thymosin, a thymic hormone. J Immunol (1971) 1.73
Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A (1987) 1.71
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem (1999) 1.70
FGF10 is an inducer and Pax6 a competence factor for lacrimal gland development. Development (2000) 1.57
Flk-1 as a target for tumor growth inhibition. Cancer Res (1996) 1.56
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res (2001) 1.55
Bronchial compression as a result of lung herniation after pneumonectomy. Thorax (1991) 1.53
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem (1998) 1.52
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Meticillin-resistant Staphylococcus aureus blood-stream infection among patients attending the emergency department of an urban tertiary-referral hospital. Ir Med J (2007) 1.47
Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J (2001) 1.44
Limitations to the identification of HIV-associated neurocognitive disorders in clinical practice. HIV Med (2013) 1.44
Orientation and control of transcription in E. coli phage lambda. Nature (1969) 1.43
Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation (2001) 1.42
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res (1997) 1.36
Conservative management of vestibular schwannomas: third review of a 10-year prospective study. Clin Otolaryngol (2008) 1.33
An inhibitory monoclonal antibody against human tissue factor. Blood (1987) 1.30
Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol (1993) 1.29
Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem (1996) 1.27
In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest (1996) 1.26
Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat (2008) 1.25
Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology (2002) 1.25
Transcriptional controls in developing bacteriophages. J Cell Physiol (1969) 1.25
Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med (1989) 1.23
Orientation of transcription for the galactose operon as determined by hybridization of gal mRNA with the separated DNA strands of coliphages lambda-dg. J Mol Biol (1968) 1.21
Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry (1992) 1.20
Identification of active tissue factor in human coronary atheroma. Circulation (1996) 1.18
Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology (1997) 1.14
Spontaneous in vitro transformation of human fibroblasts. J Natl Cancer Inst (1984) 1.14
Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br J Cancer (2012) 1.14
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14
Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery (1998) 1.13
Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proc Natl Acad Sci U S A (1986) 1.13
Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest (1993) 1.12
Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res (2001) 1.10
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer (1999) 1.10
Decompression of the spinal cord improves recovery after acute experimental spinal cord compression injury. Paraplegia (1987) 1.10
Divergent orientation of transcription from the arginine gene ECBH cluster of Escherichia coli. J Bacteriol (1974) 1.07
Glioblastoma multiforme occurring in a patient treated with gamma knife surgery. Case report and review of the literature. J Neurosurg (2001) 1.06
Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology (2003) 1.05
Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol (2001) 1.04
Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med (1995) 1.03
Identification of the transcribing DNA strand for the rII and endolysin genes of coliphage T4. J Mol Biol (1968) 1.02
Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery (1997) 1.02
GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system. Oncogene (2009) 1.02
In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res (2001) 1.01
Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles. Proc Natl Acad Sci U S A (1986) 1.01
Purification and comparison of 2',3'-cyclic nucleotide 3'-phosphohydrolases from bovine brain and spinal cord. J Neurochem (1978) 1.01
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene (1999) 1.00
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res (2001) 0.99
Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas. J Neurooncol (2001) 0.99
The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta (1994) 0.99
Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol (1994) 0.98
Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci U S A (1990) 0.98
Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest (1993) 0.98
Soft-tissue augmentation with injectable alginate and syngeneic fibroblasts. Plast Reconstr Surg (2000) 0.97
The effect of vitamin A deficiency and dietary alpha-tocopherol on the stability of rat-liver lysosomes. Biochem J (1965) 0.97
New insights into the pathogenesis of appendicitis based on immunocytochemical analysis of early immune response. J Pediatr Surg (1990) 0.96
Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro Oncol (2001) 0.96
Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer (1998) 0.96
Expression of vascular endothelial growth factor by reactive astrocytes and associated neoangiogenesis. Brain Res (2000) 0.95
Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer (2000) 0.94
Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Oncogene (1996) 0.94
Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol (1991) 0.94
Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg (1997) 0.93
Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res (2001) 0.93
Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost (2000) 0.92
Solubilization of 2',3'-cyclic nucleotide 3'-phosphohydrolase from bovine brain without detergents. Brain Res (1975) 0.92
Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol (1997) 0.91
Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol (1999) 0.91
Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol (1986) 0.91
The Italian National Registry of severe acquired brain injury: epidemiological, clinical and functional data of 1469 patients. Eur J Phys Rehabil Med (2013) 0.90